uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
uniQure BV (QURE) PT Raised to $72 at B.Riley/FBR
November 15, 2018 9:58 AM ESTB.Riley/FBR analyst Madhu Kumar raised the price target on uniQure BV (NASDAQ: QURE) to $72.00 (from $50.00) while maintaining a Buy rating.
... MoreuniQure BV (QURE) PT Raised to $65 at Cantor Fitzgerald
November 15, 2018 9:36 AM ESTCantor Fitzgerald analyst Elemer Piros raised the price target on uniQure BV (NASDAQ: QURE) to $65.00 (from $58.00) while maintaining a Overweight rating.
Piros commented, "This morning, uniQure announced initial top-line data from the Phase 2b dose-confirmation study of AMT-061 for the treatment of... More
uniQure BV (QURE) PT Raised to 'Street High' $76 at Leerink Partners
November 15, 2018 8:56 AM ESTLeerink Partners analyst Joseph Schwartz raised the price target on uniQure BV (NASDAQ: QURE) to a 'Street High' $76.00 (from $61.00) while maintaining an Outperform rating following AMT-061 data.
... MoreuniQure (QURE) Climbs 40% After Reporting Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
November 15, 2018 7:20 AM ESTuniQure (NASDAQ: QURE) Climbs 40% After Reporting Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
... More